Proteomics in cancer biomarkers discovery: Challenges and applications

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Sallam, Reem M ^a,b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ASSOCIATED PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; PEPTIDES AND PROTEINS; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; ELECTROSPRAY MASS SPECTROMETRY; GAS CHROMATOGRAPHY; HEMATOLOGIC MALIGNANCY; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SELECTED REACTION MONITORING ASSAY; SOLID TUMOR; STUDY DESIGN; TWO DIMENSIONAL ELECTROPHORESIS; ANIMAL; EARLY CANCER DIAGNOSIS; GENETICS; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; PROTEOMICS;

EID: 84929340665     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/321370     Document Type: Review

References (89)

1. L. Ding, M. C. Wendl, J. F. McMichael, and B. J. Raphael, "Expanding the computational toolbox for mining cancer genomes", Nature Reviews Genetics, vol. 15, no. 8, pp. 556-570, 2014.
2. M. S. Lawrence, P. Stojanov, C. H. Mermel et al., "Discovery and saturation analysis of cancer genes across 21 tumour types", Nature, vol. 505, no. 7484, pp. 495-501, 2014.
3. M. W. Duncan, "Good mass spectrometry and its place in good science", Journal of Mass Spectrometry, vol. 47, no. 6, pp. 795-809, 2012.
4. M. Wilhelm, J. Schlegl, H. Hahne et al., "Mass-spectrometrybased draft of the human proteome", Nature, vol. 509, no. 7502, pp. 582-587, 2014.
5. F. Meric-Bernstam, A. Akcakanat, H. Chen et al., "Influence of biospecimen variables on proteomic biomarkers in breast cancer", Clinical Cancer Research, vol. 20, no. 14, pp. 3870-3883, 2014.
6. G. Poste, "Bring on the biomarkers", Nature, vol. 469, no. 7329, pp. 156-157, 2011.
7. N. Donnelly and Z. Storchová, "Dynamic karyotype, dynamic proteome: buffering the effects of aneuploidy", Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1843, no. 2, pp. 473-481, 2014.
8. W. E. Balch, R. I. Morimoto, A. Dillin, and J. W. Kelly, "Adapting proteostasis for disease intervention", Science, vol. 319, no. 5865, pp. 916-919, 2008.
9. J. Adams, "The proteasome: a suitable antineoplastic target", Nature Reviews Cancer, vol. 4, no. 5, pp. 349-360, 2004.
10. R. Mosca, A. Céol, and P. Aloy, "Interactome3D: adding structural details to protein networks", Nature Methods, vol. 10, no. 1, pp. 47-53, 2013.
11. S. Gulati, T. M. K. Cheng, and P. A. Bates, "Cancer networks and beyond: interpreting mutations using the human interactome and protein structure", Seminars in Cancer Biology, vol. 23, no. 4, pp. 219-226, 2013.
12. O. J. R. Gustafsson, J. S. Eddes, S. Meding, S. R. McColl, M. K. Oehler, and P. Hoffmann, "Matrix-assisted laser desorption/ionization imaging protocol for in situ characterization of tryptic peptide identity and distribution in formalin-fixed tissue", Rapid Communications in Mass Spectrometry, vol. 27, no. 6, pp. 655-670, 2013.
13. S. Meding, K. Martin, O. J. R. Gustafsson et al., "Tryptic peptide reference data sets for MALDI imaging mass spectrometry on formalin-fixed ovarian cancer tissues", Journal of Proteome Research, vol. 12, no. 1, pp. 308-315, 2013.
14. M. Shipitsin, C. Small, S. Choudhury et al., "Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error", British Journal of Cancer, vol. 111, no. 6, pp. 1201-1212, 2014.
15. S. S. Hori and S. S. Gambhir, "Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations", Science Translational Medicine, vol. 3, no. 109, pp. 109-116, 2011.
16. D. Konforte and E. P. Diamandis, "Is early detection of cancer with circulating biomarkers feasible?" Clinical Chemistry, vol. 59, no. 1, pp. 35-37, 2013.
17. B. M. Nolen and A. E. Lokshin, "Protein biomarkers of ovarian cancer: the forest and the trees", Future Oncology, vol. 8, no. 1, pp. 55-71, 2012.
18. M. E. H. Hammond and S. E. Taube, "Issues and barriers to development of clinically useful tumormarkers: a development pathway proposal", Seminars in Oncology, vol. 29, no. 3, pp. 213-221, 2002.
19. M. S. Pepe, R. Etzioni, Z. Feng et al., "Phases of biomarker development for early detection of cancer", Journal of the National Cancer Institute, vol. 93, no. 14, pp. 1054-1061, 2001.
20. M. S. Pepe, Z. Feng, H. Janes, P. M. Bossuyt, and J. D. Potter, "Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design", Journal of the National Cancer Institute, vol. 100, no. 20, pp. 1432-1438, 2008.
21. M. A. Baldwin, "Protein identification by mass spectrometry: issues to be considered", Molecular and Cellular Proteomics, vol. 3, no. 1, pp. 1-9, 2004.
22. S. A. Carr, S. E. Abbatiello, B. L. Ackermann et al., "Targeted peptide measurements in biology and medicine: best practices formass spectrometry-based assay development using a fit-forpurpose approach", Molecular & Cellular Proteomics, vol. 13, no. 3, pp. 907-917, 2014.
23. L. G. Longsworth, T. Shedlovsky, and D. A. Macinnes, "Electrophoretic patterns of normal and pathological human blood serum and plasma", Journal of Experimental Medicine, vol. 70, no. 4, pp. 399-413, 1939.
24. S. Hanash and A. Taguchi, "Thegrand challenge to decipher the cancer proteome", Nature Reviews Cancer, vol. 10, no. 9, pp. 652-660, 2010.
25. S. M. Hanash, L. J. Baier, L. McCurry, and S. A. Schwartz, "Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis", Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 3, pp. 807-811, 1986.
26. J. M. A. Moreira, G. Ohlsson, P. Gromov et al., "Bladder cancerassociated protein, a potential prognostic biomarker in human bladder cancer", Molecular and Cellular Proteomics, vol. 9, no. 1, pp. 161-177, 2010.
27. L. A. Liotta, M. Ferrari, and E. Petricoin, "Clinical proteomics: written in blood", Nature, vol. 425, no. 6961, p. 905, 2003.
28. K. Fujii, T. Kondo, M. Yamada, K. Iwatsuki, and S. Hirohashi, "Toward a comprehensive quantitative proteome database: protein expression map of lymphoid neoplasms by 2-D DIGE and MS", Proteomics, vol. 6, no. 17, pp. 4856-4876, 2006.
29. B. F. Cravatt, G. M. Simon, and J. R. Yates III, "The biological impact of mass-spectrometry-based proteomics", Nature, vol. 450, no. 7172, pp. 991-1000, 2007.
30. N. Siuti and N. L. Kelleher, "Decoding protein modifications using top-downmass spectrometry", Nature Methods, vol. 4, no. 10, pp. 817-821, 2007.
31. A. I. Nesvizhskii, O. Vitek, and R. Aebersold, "Analysis and validation of proteomic data generated by tandem mass spectrometry", Nature Methods, vol. 4, no. 10, pp. 787-797, 2007.
32. T. Bartke, J. Borgel, and P. A. Di Maggio, "Proteomics in epigenetics: new perspectives for cancer research", Briefings in Functional Genomics, vol. 12, no. 3, pp. 205-218, 2013.
33. E. Agwa and P. C. Ma, "Overview of various techniques/platforms with critical evaluation of each", Current Treatment Options in Oncology, vol. 14, no. 4, pp. 623-633, 2013.
34. Q. Wang, R. Chaerkady, J. Wu et al., "Mutant proteins as cancerspecific biomarkers", Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 6, pp. 2444-2449, 2011.
35. M. S. Kim, S. Kwon, T. Kim, E. S. Lee, and J.-K. Park, "Quantitative proteomic profiling of breast cancers using a multiplexed microfluidic platform for immunohistochemistry and immunocytochemistry", Biomaterials, vol. 32, no. 5, pp. 1396-1403, 2011.
36. M. Shipitsin, C. Small, E. Giladi et al., "Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality", Proteome Science, vol. 12, article 40, 2014.
37. P. Oh, J. E. Testa, P. Borgstrom, H. Witkiewicz, Y. Li, and J. E. Schnitzer, "In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors", Nature Medicine, vol. 20, no. 9, pp. 1062-1068, 2014.
38. J. A. Ludwig and J. N. Weinstein, "Biomarkers in cancer staging, prognosis and treatment selection", Nature Reviews Cancer, vol. 5, no. 11, pp. 845-856, 2005.
39. R. Schiess, B. Wollscheid, and R. Aebersold, "Targeted proteomic strategy for clinical biomarker discovery", Molecular Oncology, vol. 3, no. 1, pp. 33-44, 2009.
40. J. R. Whiteaker, C. Lin, J. Kennedy et al., "Atargeted proteomicsbased pipeline for verification of biomarkers in plasma", Nature Biotechnology, vol. 29, no. 7, pp. 625-634, 2011.
41. R. Huttenhain, M. Soste, N. Selevsek et al., "Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics", Science Translational Medicine, vol. 4, no. 142, p. 142ra94, 2012.
42. A. Taguchi, K. Politi, S. J. Pitteri et al., "Lung cancer signatures in plasma based on proteome profiling of mouse tumor models", Cancer Cell, vol. 20, no. 3, pp. 289-299, 2011.
43. T. Geiger, S. F. Madden, W. M. Gallagher, J. Cox, and M. Mann, "Proteomic portrait of human breast cancer progression identifies novel prognostic markers", Cancer Research, vol. 72, no. 9, pp. 2428-2439, 2012.
44. S. J. Pitteri, K. S. Kelly-Spratt, K. E. Gurley et al., "Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression", Cancer Research, vol. 71, no. 15, pp. 5090-5100, 2011.
45. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013", CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
46. F. Leung, E. P. Diamandis, and V. Kulasingam, "Ovarian cancer biomarkers: current state and future implications from highthroughput technologies", Advances in Clinical Chemistry, vol. 66, pp. 25-77, 2014.
47. S. Vaughan, J. I. Coward, R. C. Bast et al., "Rethinking ovarian cancer: recommendations for improving outcomes", Nature Reviews Cancer, vol. 11, no. 10, pp. 719-725, 2011.
48. Y. Mechref, Y. Hu, A. Garcia, and A. Hussein, "Identifying cancer biomarkers by mass spectrometry-based glycomics", Electrophoresis, vol. 33, no. 12, pp. 1755-1767, 2012.
49. B. Adamczyk, T. Tharmalingam, and P. M. Rudd, "Glycans as cancer biomarkers", Biochimica et Biophysica Acta, vol. 1820, no. 9, pp. 1347-1353, 2012.
50. W. R. Alley Jr., J. A. Vasseur, J. A. Goetz et al., "N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients", Journal of Proteome Research, vol. 11, no. 4, pp. 2282-2300, 2012.
51. K. Kim, L. R. Ruhaak, U. T. Nguyen et al., "Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer", Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 4, pp. 611-621, 2014.
52. J. N. Arnold, R. Saldova, U. M. Abd Hamid, and P. M. Rudd, "Evaluation of the serumN-linked glycome for the diagnosis of cancer and chronic inflammation", Proteomics, vol. 8, no. 16, pp. 3284-3293, 2008.
53. A. A. Alfadda, A. A. Turjoman, A. S. Moustafa et al., "A proteomic analysis of excreted and circulating proteins from obese patients following two different weight-loss strategies", Experimental Biology and Medicine, vol. 239, no. 5, pp. 568-580, 2014.
54. T. Zhang, X. Wu, C. Ke et al., "Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling", Journal of Proteome Research, vol. 12, no. 1, pp. 505-512, 2013.
55. J. Chen, L. Zhou, X. Zhang et al., "Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatographymass spectrometry methods: differential metabolite discovery specific to ovarian cancer", Electrophoresis, vol. 33, no. 22, pp. 3361-3369, 2012.
56. C. Ke, Y. Hou, H. Zhang et al., "Large-scale profiling of metabolic dysregulation in ovarian cancer", International Journal of Cancer, vol. 136, no. 3, pp. 516-26, 2015.
57. V. O. Shender, M. S. Pavlyukov, R. H. Ziganshin et al., "Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication", Molecular & Cellular Proteomics, vol. 13, no. 12, pp. 3558-3571, 2014.
58. C. R. Smith, I. Batruch, J. Bauça et al., "Deciphering the peptidome of urine from ovarian cancer patients and healthy controls", Clinical Proteomics, vol. 11, article 23, 2014.
59. Z. Xu, C. Wu, F. Xie et al., "Comprehensive quantitative analysis of Ovarian and breast cancer tumor peptidomes", Journal of Proteome Research, vol. 14, no. 1, pp. 422-433, 2015.
60. A. Bery, F. Leung, C. R. Smith, E. P. Diamandis, and V. Kulasingam, "Deciphering the ovarian cancer ascites fluid peptidome", Clinical Proteomics, vol. 11, no. 1, article 13, 2014.
61. K. S. Anderson, D. W. Cramer, S. Sibani et al., "Autoantibody signature for the serologic detection of ovarian cancer", Journal of Proteome Research, vol. 14, no. 1, pp. 578-586, 2015.
62. Y. S. Cho-Chung, "Autoantibody biomarkers in the detection of cancer", Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1762, no. 6, pp. 587-591, 2006.
63. L. Gortzak-Uzan, A. Ignatchenko, A. I. Evangelou et al., "A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers", Journal of Proteome Research, vol. 7, no. 1, pp. 339-351, 2008.
64. E. R. Hoskins, B. L. Hood, M. Sun, T. C. Krivak, R. P. Edwards, and T. P. Conrads, "Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation", PLoS ONE, vol. 6, no. 9, Article ID e25056, 2011.
65. L. E. Moore, R. M. Pfeiffer, Z. Zhang, K. H. Lu, E. T. Fung, and R. C. Bast Jr., "Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial", Cancer, vol. 118, no. 1, pp. 91-100, 2012.
66. L. E. Moore, E. T. Fung, M. McGuire et al., "Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population", Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 9, pp. 1641-1646, 2006.
67. E. F. Petricoin, A. M. Ardekani, B. A. Hitt et al., "Use of proteomic patterns in serum to identify ovarian cancer", The Lancet, vol. 359, no. 9306, pp. 572-277, 2002.
68. R. Longuespée, C. Boyon, A. Desmons et al., "Ovarian cancer molecular pathology", Cancer and Metastasis Reviews, vol. 31, no. 3-4, pp. 713-732, 2012.
69. A. Toss, E. De Matteis, E. Rossi et al., "Ovarian cancer: can proteomics give new insights for therapy and diagnosis?" International Journal of Molecular Sciences, vol. 14, no. 4, pp. 8271-8290, 2013.
70. T. Walsh, S. Casadei, K. H. Coats et al., "Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer", The Journal of the American Medical Association, vol. 295, no. 12, pp. 1379-1388, 2006.
71. C. Fuseya, A. Horiuchi, A. Hayashi et al., "Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis", Human Pathology, vol. 43, no. 11, pp. 1964-1972, 2012.
72. N. J. Engel, P. Gordon, D. L. Thull et al., "A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer", Familial Cancer, vol. 11, no. 3, pp. 419-427, 2012.
73. B. Rungruang, B. L. Hood, M. Sun, E. Hoskins, T. P. Conrads, and K. K. Zorn, "Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome", Journal of Proteome Research, vol. 9, no. 11, pp. 6071-6076, 2010.
74. Y. L. Li, F. Ye, X. D. Cheng et al., "Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer", European Journal of Cancer, vol. 46, no. 11, pp. 2104-2118, 2010.
75. S. Elschenbroich, V. Ignatchenko, B. Clarke et al., "In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry", Journal of Proteome Research, vol. 10, no. 5, pp. 2286-2299, 2011.
76. L. Cortesi, E. Rossi, L. D. Casa et al., "Protein expression patterns associated with advanced stage ovarian cancer", Electrophoresis, vol. 32, no. 15, pp. 1992-2003, 2011.
77. S. Waldemarson, M. Krogh, A. Alaiya et al., "Protein expression changes in ovarian cancer during the transition from benign to malignant", Journal of Proteome Research, vol. 11, no. 5, pp. 2876-2889, 2012.
78. N. Musrap, G. S. Karagiannis, P. Saraon, I. Batruch, C. Smith, and E. P. Diamandis, "Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction", Journal of Proteomics, vol. 103, pp. 204-215, 2014.
79. D. M. Roque, N. Buza, M. Glasgow et al., "Class III betatubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel", Clinical and Experimental Metastasis, vol. 31, no. 1, pp. 101-110, 2014.
80. K. K. Zorn, T. Bonome, L. Gangi et al., "Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer", Clinical Cancer Research, vol. 11, no. 18, pp. 6422-6430, 2005.
81. M. S. Anglesio, J. George, H. Kulbe et al., "IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer", Clinical Cancer Research, vol. 17, no. 8, pp. 2538-2548, 2011.
82. D. S. P. Tan, R. E. Miller, and S. B. Kaye, "New perspectives on molecular targeted therapy in ovarian clear cell carcinoma", British Journal of Cancer, vol. 108, no. 8, pp. 1553-1559, 2013.
83. J. W. Lee, D. Figeys, and J. Vasilescu, "Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers", Advances in Cancer Research, vol. 96, pp. 269-298, 2007.
84. S. Cohen, R. A. Fava, and S. T. Sawyer, "Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver", Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 20, pp. 6237-6241, 1982.
85. A. M. Gholami, H. Hahne, Z. Wu et al., "Global proteome analysis of the NCI-60 cell line panel", Cell Reports, vol. 4, no. 3, pp. 609-620, 2013.
86. P. Cohen, "Protein kinases-the major drug targets of the twenty-first century?" Nature Reviews Drug Discovery, vol. 1, no. 4, pp. 309-315, 2002.
87. S. Knapp, P. Arruda, J. Blagg et al., "A public-private partnership to unlock the untargeted kinome", Nature Chemical Biology, vol. 9, no. 1, pp. 3-7, 2013.
88. H. Wiech, J. Buchner, R. Zimmermann, and U. Jakob, "Hsp90 chaperones protein folding in vitro", Nature, vol. 358, no. 6382, pp. 169-170, 1992.
89. R. Garcia-Carbonero, A. Carnero, and L. Paz-Ares, "Inhibition of HSP90 molecular chaperones: moving into the clinic", The Lancet Oncology, vol. 14, no. 9, pp. e358-e369, 2013.